Zeng SY, Yuan J, Lv M. Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report. World J Clin Cases 2022; 10(31): 11617-11624 [PMID: 36387802 DOI: 10.12998/wjcc.v10.i31.11617]
Corresponding Author of This Article
Shu-Ying Zeng, CCST, Doctor, MSc, PhD, Doctor, Department of Oncology, The First People's Hospital of Longquanyi District Chengdu, No. 39 Mudan Street, Jinjiang District, Chengdu 652532, Sichuan Province, China. 18982193611@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2022; 10(31): 11617-11624 Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11617
Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
Shu-Ying Zeng, Jin Yuan, Min Lv
Shu-Ying Zeng, Jin Yuan, Min Lv, Department of Oncology, The First People's Hospital of Longquanyi District Chengdu, Chengdu 652532, Sichuan Province, China
Author contributions: Zeng SY contributed to protocol/project development, data collection or management, data analysis, and manuscript writing/editing; Yuan J contributed to data collection and manuscript editing; Lv M contributed to protocol/project development and manuscript editing.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Ying Zeng, CCST, Doctor, MSc, PhD, Doctor, Department of Oncology, The First People's Hospital of Longquanyi District Chengdu, No. 39 Mudan Street, Jinjiang District, Chengdu 652532, Sichuan Province, China. 18982193611@163.com
Received: July 14, 2022 Peer-review started: July 14, 2022 First decision: August 1, 2022 Revised: August 19, 2022 Accepted: September 21, 2022 Article in press: September 21, 2022 Published online: November 6, 2022 Processing time: 104 Days and 20.2 Hours
Abstract
BACKGROUND
There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now.
CASE SUMMARY
In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal.
CONCLUSION
Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC.
Core Tip: Herein, we present the case of a lymphoepithelioma-like carcinoma (LELC) patient who was successfully treated with sintilimab combined with paclitaxel and carboplatin. Recent literature on LELC is also reviewed and discussed for future avenues for LELC research.
